trending Market Intelligence /marketintelligence/en/news-insights/trending/Y3pkJIncMmQ8oEm6TWRhgQ2 content esgSubNav
In This List

AstraZeneca's Farxiga approved to cut admission risk in US diabetes patients

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AstraZeneca's Farxiga approved to cut admission risk in US diabetes patients

SNL Image

AstraZeneca PLC said the U.S. Food and Drug Administration approved Farxiga to cut the risk of hospitalization for heart failure in certain patients with type 2 diabetes.

Farxiga, or dapagliflozin, can now be used by adult patients with type 2 diabetes and established cardiovascular disease or multiple heart-related risk factors to reduce the risk of hospitalization for heart failure.

The approval is based on data from a late-stage study called Declare-Timi 58, in which Farxiga was shown to reduce the likelihood of hospitalization for heart failure or heart-related death, the Cambridge, U.K.-based drugmaker said.

Taking Farxiga cut hospitalizations for heart failure by 36% in patients with a reduced ejection fraction — a measure of how much blood the heart pumps out with each contraction. For those without reduced ejection fraction, the drop in hospitalizations was 24%.

In August, the European Commission approved a label update for Farxiga — marketed in the EU as Forxiga — expanding the medicine's marketing authorization to include positive cardiovascular outcomes. Farxiga is being evaluated by Chinese regulators, with a decision expected in the first half of 2020.

Farxiga belongs to a class of drugs known as SGLT-2 inhibitors — along with Johnson & Johnson's Invokana and Boehringer Ingelheim GmbH's Jardiance — and is approved to improve glycemic control in adults with type 2 diabetes. This class of therapies, also known as gliflozin drugs, works by absorbing glucose via the kidneys so that excess glucose is passed out of the body via urination.